[1]Wapinski O,Chang HY. Long noncoding RNAs and human disease. Trends Cell Biol. 2011;21:354-361.
[2]Guttman M, Amit I, Garber M,et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature.2009;458:223-227.
[3]Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc. Natl Acad. Sci.USA. 2009;106:11667-11672.
[4]Rinn JL, Kertesz M, Wang JK, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.Cell.2007;129:1311-1323 .
[5]Pauli A, Rinn JL, Schier AF. Non-coding RNAs as regulators of embryogenesis. Nature Rev. Genet.2011;12:136-149.
[6]Guttman M, Rinn JL, Modular regulatory principles of large non-coding RNAs. Nature.2012;482:339-346.
[7]Cesana M,Cacchiarelli D,Legnini I,et al.A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA.Cell.2011;147:358-369.
[8]Kretz M,Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non coding RNA TINCR.Nature. 2013;493:231-235.
[9]Kretz M,Webster DE,Flockhart RJ,et al.Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev.2012;26:338-343.
[10]Ng SY, Johnson R, Stanton LW. Human long non coding RNAs promote pluripotency and neuronal differentiation by association with chromatin modifiers and transcription factors. EMBO J.2011;31:522-533.
[11]Basem M,Abdallah MK.The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: Current status and future perspectives.J Cell Physiol.2009; 218:9-12.
[12]Chen D, Zhao M,Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004; 22: 233-241.
[13]Brooke G,Cook M, Blair C,et al.Therapeutic applications of mesenchymal stromal cells.Semin Cell Dev Biol.2007;18: 846–858.
[14]Tsuchida K.Targeting myostatin for therapies against muscle‐wasting disorders. Curr Opin Drug Discov Devel.2008;11(4): 487-494.
[15]Hamrick MW, Arounleut P, Kellum E,et al.Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury. J Trauma. 2010; 69(3):579-83.
[16]Connelly LB, Woolf A, Brooks P.Cost-effectiveness of interventions for musculoskeletal conditions. Disease control in developing countries. Oxford, U.K. Oxford University Press.2006;963-980.
[17]Connelly LB, Supangan R.The economic costs of road traffic crashes: Australia, states and territories.Accid Anal Prev.2006; 38(6):1087-93.
[18]Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res.2007; 22(3):465-475.
[19]Marks R. Hip fracture epidemiological trends, outcomes, and risk factors, 1970-2009.Int J Gen Med.2010;3:1-17.
[20]Hamrick M. JMNI special issue: basic science and mechanisms of muscle-bone interactions.J Musculoskelet Neuronal Interact.2010;10(1):1-2. |